Advanced Cell Diagnostics Raises $22M in Series C Equity Financing

acdAdvanced Cell Diagnostics, Inc. (ACD), a Hayward, California-based leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, raised $22m in Series C equity financing.

The round was led by growth equity investor Summit Partners with participation from Kenson Ventures and existing investors Morningside Ventures and New Leaf Venture Partners. Harrison Miller, a Managing Director with Summit Partners, who will join ACD’s Board of Directors.

Proceeds from the financing will be used to accelerate the entry into the research and clinical diagnostics markets and launch new innovative technology platforms based on the company’s proprietary RNAscope® technology.

ACD is led by Dr. Yuling Luo, Founder, President and CEO.



Join the discussion